-
The results of the first-line clinical study of Hausen Pharmaceuticals Amelia will be announced at ASCO
Time of Update: 2021-07-06
independently developed a category 1 innovative drug Amelo® (Ametinib mesylate) for the first-line treatment of EGFR The data of the Phase III clinical study of sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) will be announced at the 2021 ASCO annual meeting .
-
Brooks Automation, the parent company of Jinwei Zhizhi, plans to split into two independent listed companies
Time of Update: 2021-07-06
On May 10, 2021, Brooks Automation, the parent company of Jinwei Zhizhi, announced its plan to split into two independent listed companies to establish a life science company and an automation company with a focus on business and rapid growth .
-
Chuangsheng Group announced in ASCO the results of a phase I updated clinical study of the pH-dependent PD-L1 antibody MSB2311 in the treatment of advanced solid tumors and hematological malignancies
Time of Update: 2021-07-06
Chuangsheng Group, an international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical R&D, clinical and production, announced the release of its pH-dependent PD-L1 antibody MSB2311 in summary form at the 2021 American Society of Clinical Oncology (ASCO) annual meeting Update on safety and efficacy data of the Phase I clinical study (NCT04272944) in patients with advanced solid tumors and hematological malignancies in China (Abstract number: #e14547, May 19, 2021, 5:00 PM, Eastern Time) .
-
European Wellness and Yantai Dongci Hospital build a regenerative medicine center in Shandong, China
Time of Update: 2021-07-06
European Wellness Biomedical Group has signed a memorandum of understanding with Yantai Dongci Hospital to build a multi-million dollar exclusive project Regenerative Medicine Center (Regenerative Medicine Center) in Shandong, China .
-
Hisun Pharmaceutical: Linezolid tablets obtained drug registration certificate
Time of Update: 2021-07-06
On June 8, Hisun Pharmaceuticals stated that it had recently received the "Drug Registration Certificate" for linezolid tablets approved and issued by the National Medical Products Administration .
7499 million, of which the domestic market sales were approximately 3,244.
-
Teyi Pharmaceutical Metronidazole Tablets and Clindamycin Hydrochloride Capsules Passed the Consistency Evaluation
Time of Update: 2021-07-06
Today, Teyi Pharmaceutical issued an announcement stating that the company had recently obtained the "Metronidazole Tablets" and "Clindamycin Hydrochloride Capsules" approved and issued by the National Medical Products Administration in the "Drug Supplementary Application Approval Notice".
-
Arnold Pharma submits a clinical trial application for the self-developed oral PD-L1 inhibitor AN4005
Time of Update: 2021-07-06
"As a small molecule PD-L1 inhibitor, AN4005 has shown good anti-tumor activity, and has great potential in monotherapy and in combination with other products of the company in the future .
-
Hanyu Pharmaceutical's Thymus Method for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-07-06
The status of “drug approval documents pending” indicates that the company The new consistency evaluation of the thymus method for injection has been approved by the State Food and Drug Administration, and the company has not yet received a formal drug approval .
-
Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half-life
Time of Update: 2021-07-06
Bristol Myers Squibb will use Xencor's technology to extend the half-life of SARS-CoV-2 neutralizing monoclonal antibody combination therapy .
The company hopes that this technology can extend the half-life of the new SARS-CoV-2 antibody combination therapy used to treat or prevent COVID-19 .
-
Deqi Pharmaceuticals announces the completion of quantitative system pharmacology modeling of ATG-101 to promote the initiation of phase I clinical trials
Time of Update: 2021-07-06
Through Applied With the model provided by BioMath, Deqi has a thorough understanding of the anti-tumor mechanism of ATG-101, and we are able to better design the first human trial and other clinical trials .
-
"Magic bullet" ADC drug 10 billion gold track competition intensifies!
Time of Update: 2021-07-06
Recently, the domestic news about ADC drug research and development dynamics refreshed the screen On May 18, the innovative ADC introduced by Xinma Biology is planned to be included in the breakthrough treatment product; On May 17, Genting Xinyao Trodelvy (Gosartuzumab for injection)’s biological product marketing authorization application was accepted by the State Food and Drug Administration.
-
The world's first: CStone Pharmaceuticals announces that the Phase III registration clinical trial of sugarizumab for the treatment of non-small cell lung cancer has reached the primary endpoint, and it plans to submit a new drug listing application
Time of Update: 2021-07-06
" CStone Pharmaceuticals plans to submit a new drug application (NDA) for sugarizumab to the China National Medical Products Administration for the treatment of phase III NSCLC indications in the near future, and will work closely with EQRx, including the U.
-
Philips Medical Online Mall debuts at CMEF in spring 2021
Time of Update: 2021-07-06
Today, at the "2021 China International Medical Equipment Expo" (CMEF), Philips released the "Philips Medical Online Mall" to provide professional users with "cloud platform" services, including the purchase of medical equipment, viewing equipment training demonstrations, and obtaining targeted solutions for professional services to complete the follow-up product upgrades and order management .
-
Xuzhenda cooperates with Imena and Eurolink to create a one-stop multi-omics one-stop service platform
Time of Update: 2021-07-06
To this end, Xu Zhenda introduced Immena's sequencing platform, TSO500 tumor panel, Eurolink's proteomics detection technology, and other single-cell-based multi-omics detection technologies to cooperate to promote the development of precision medicine .
-
400 billion market fight!
Time of Update: 2021-07-06
It can be seen that European and American pharmaceutical companies have an absolute advantage in the global peptide market, while the vast majority of domestic companies focus on peptide generics, and there are only a handful of companies that have the ability to develop new drugs .
-
Enterprise Interview with Hangzhou Huafei Chemical Co., Ltd. and "Video Cloud Negotiation" to Link Global Pharmaceutical Buyers
Time of Update: 2021-06-30
In order to help domestic pharmaceutical companies to secure orders, stabilize the market, promote development, and easily link overseas customers to reach "meetings" under the epidemic, PharmaSources.
-
Qilu enters the market with annual sales of $1.9 billion blockbuster drug and Chengdu Beite competes for the first imitation
Time of Update: 2021-06-17
Figure 1: The status of products declared by Qilu Pharmaceutical Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars) Source: Mynet.
Figure 1: The status of products declared by Qilu Pharmaceutical Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars) Source: Mynet.
-
Puli Pharmaceuticals successfully won the best-selling anticoagulant ANDA in a patent challenge
Time of Update: 2021-06-08
Source: Company announcement, Mi Neiwang database Medical Network, June 2 News On May 31, Puli Pharmaceuticals issued an announcement stating that the company had recently received a notice of approval for the marketing of a generic bivalrudine for injection issued by the FDA.
-
Yiling Pharmaceutical won the "2021 China Brand (Industry) Top Ten Innovative Enterprises"
Time of Update: 2021-06-04
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
-
Shandong pharmaceutical companies show their power!
Time of Update: 2021-06-01
Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
